Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.
Cancer
Clinical trial
Generalized linear mixed model
Health-related quality of life
Longitudinal analysis
Time to deterioration
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
accepted:
06
08
2020
pubmed:
19
8
2020
medline:
5
3
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal statistical approaches were mainly used to study HRQoL: linear mixed models (LMM) or time-to-event models for time to deterioration/time until definitive deterioration (TTD/TUDD). Recently, an alternative strategy based on generalized linear mixed models for categorical data has also been proposed: the longitudinal partial credit model (LPCM). The objective of this article is to evaluate these methods and to propose recommendations to standardize longitudinal analysis of HRQoL data in cancer clinical trials. The three methods are first described and compared through statistical, methodological, and practical arguments, then applied on real HRQoL data from clinical cancer trials or published prospective databases. In total, seven French studies from a collaborating group were selected with longitudinal collection of QLQ-C30. Longitudinal analyses were performed with the three approaches using SAS, Stata and R software. We observed concordant results between LMM and LPCM. However, discordant results were observed when we considered the TTD/TUDD approach compared to the two previous methods. According to methodological and practical arguments discussed, the approaches seem to provide additional information and complementary interpretations. LMM and LPCM are the most powerful methods on simulated data, while the TTD/TUDD approach gives more clinically understandable results. Finally, for single-item scales, LPCM is more appropriate. These results pledge for the recommendation to use of both the LMM and TTD/TUDD longitudinal methods, except for single-item scales, establishing them as the consensual methods for publications reporting HRQoL.
Identifiants
pubmed: 32809099
doi: 10.1007/s11136-020-02605-3
pii: 10.1007/s11136-020-02605-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-103Subventions
Organisme : SIRIC
ID : Grant INCa_Inserm_DGOS_12553
Organisme : IReSP
ID : AAR2013-01
Références
Osoba, D. (2011). Health-related quality of life and cancer clinical trials. Therapeutic Advances in Medical Oncology, 3(2), 57–71.
doi: 10.1177/1758834010395342
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute, 85(5), 365–376.
doi: 10.1093/jnci/85.5.365
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. on behalf of the E. Q. of L. Group. (2001). EORTC QLQ-C30 Scoring Manual (3rd edition).
Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology, 34(16), 1953–1956.
doi: 10.1200/JCO.2014.56.7974
Kiebert, G. M., Curran, D., & Aaronson, N. K. (1998). Quality of life as an endpoint in EORTC clinical trials european organization for research and treatment for cancer. Statistics in Medicine, 17(57), 561–569.
doi: 10.1002/(SICI)1097-0258(19980315/15)17:5/7<561::AID-SIM803>3.0.CO;2-S
Hamel, J.-F., Saulnier, P., Pe, M., Zikos, E., Musoro, J., Coens, C., et al. (2017). A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials. European Journal of Cancer, 83, 166–176.
doi: 10.1016/j.ejca.2017.06.025
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., et al. (2014). Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 709–722.
doi: 10.1056/NEJMoa1308345
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., et al. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699–708.
doi: 10.1056/NEJMoa1308573
Fairclough, D. L. (2002). Design and Analysis of Quality of Life Studies in Clinical Trials. (Boca Raton: Chapman and Hall, Ed.).
Anota, A., Hamidou, Z., Paget-Bailly, S., Chibaudel, B., Bascoul-Mollevi, C., Auquier, P., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research, 24(1), 5–18.
doi: 10.1007/s11136-013-0583-6
Barbieri, A., Peyhardi, J., Conroy, T., Gourgou, S., Lavergne, C., Mollevi, C. (2017). Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials. BMC Medical Research Methodology, 17(1).
Barbieri, A., Anota, A., Conroy, T., Gourgou-Bourgade, S., Juzyna, B., Bonnetain, F., et al. (2016). Applying the longitudinal model from item response theory to assess health-related quality of life in the PRODIGE 4/ACCORD 11 randomized trial. Medical Decision Making, 36(5), 615–628.
doi: 10.1177/0272989X15621883
Anota, A., Barbieri, A., Savina, M., Pam, A., Gourgou-Bourgade, S., Bonnetain, F., et al. (2014). Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study. Health and Quality of Life Outcomes, 12(1), 1326.
Charton, E., Cuer, B., Cottone, F., Efficace, F., Touraine, C., Hamidou, Z., et al. (2020). Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Quality of Life Research, 29(4), 867–878.
doi: 10.1007/s11136-019-02367-7
Van der Linden, W. J., Hambleton, R. K. (1997). Handbook of Modern Item Response Theory (Vol. Springer Verlag, New York).
Bascoul-Mollevi Caroline, Castan Florence, Azria David, Gourgou-Bourgade Sophie. (2015). EORTC QLQ-C30 descriptive analysis with the qlqc30 command. The Stata Journal, pp. 1060–1074. ( https://www.stata-journal.com/article.html?article=dm0084 ).
Bascoul-Mollevi, C., Savina, M., Anota, A., Barbieri, A., Azria, D., Bonnetain, F., et al. (2018). Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD. Computer Methods and Programs in Biomedicine, 158, 153–159.
doi: 10.1016/j.cmpb.2018.02.010
Anota, A., Savina, M., Bascoul-Mollevi, C., Bonnetain, F. (2017). QoLR: An R package for the longitudinal analysis of health-related quality of life in oncology. Journal of Statistical Software, p. Vol 77: Issue 12. ( https://www.jstatsoft.org/article/view/v077i12 ).
Troxel, A. B., Fairclough, D. L., Curran, D., & Hahn, E. A. (1998). Statistical analysis of quality of life with missing data in cancer clinical trials. Statistics in Medicine, 17(5–7), 653–666.
doi: 10.1002/(SICI)1097-0258(19980315/15)17:5/7<653::AID-SIM812>3.0.CO;2-M
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., et al. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): Results from a double-blind, phase 3, randomised controlled trial. The Lancet Oncology, 19(8), 1117–1125.
doi: 10.1016/S1470-2045(18)30333-4
Azria, D., Belkacemi, Y., Romieu, G., Gourgou, S., Gutowski, M., Zaman, K., et al. (2010). Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. The lancet oncology, 11(3), 258–265.
doi: 10.1016/S1470-2045(10)70013-9
Carayol, M., Romieu, G., Bleuse, J. P., Senesse, P., Gourgou-Bourgade, S., Sari, C., et al. (2013). Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. Contemporary Clinical Trials, 36, 531–543.
doi: 10.1016/j.cct.2013.09.016
Carayol, M., Ninot, G., Senesse, P., Bleuse, J.-P., Gourgou, S., Sancho-Garnier, H., et al. (2019). Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: The “APAD1” randomized controlled trial. BMC cancer, 19(1), 737.
doi: 10.1186/s12885-019-5896-6
Dabakuyo, T. S., Guillemin, F., Conroy, T., Velten, M., Jolly, D., Mercier, M., et al. (2013). Response shift effects on measuring post-operative quality of life among breast cancer patients: A multicenter cohort study. Quality of life research, 22(1), 1–11.
doi: 10.1007/s11136-012-0135-5
Hebbar, M., Chibaudel, B., Andre, T., Mineur, L., Smith, D., Louvet, C., et al. (2015). FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): A pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Annals of Oncology, 26, 1040.
doi: 10.1093/annonc/mdv141
Conroy, T., Galais, M.-P., Raoul, J.-L., Bouché, O., Gourgou-Bourgade, S., Douillard, J.-Y., et al. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. The lancet oncology, 15(3), 305–314.
doi: 10.1016/S1470-2045(14)70028-2
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine, 364(19), 1817–1825.
doi: 10.1056/NEJMoa1011923
Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., et al. (2014). Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF†. Annals of Oncology, 25(7), 1442–1447.
doi: 10.1093/annonc/mdu148
Musoro, Z. J., Hamel, J.-F., Ediebah, D. E., Cocks, K., King, M. T., Groenvold, M., et al. (2018). Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. British Medical Journal Open, 8(1), e019117.
Taphoorn, M. J. B., Henriksson, R., Bottomley, A., Cloughesy, T., Wick, W., Mason, W. P., et al. (2015). Health-related quality of life in a randomized phase iii study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. Journal of Clinical Oncology, 33(19), 2166–2175.
doi: 10.1200/JCO.2014.60.3217
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA, 309(8), 814–822.
doi: 10.1001/jama.2013.879
Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. The Lancet. Oncology, 17(11), e510–e514.
doi: 10.1016/S1470-2045(16)30510-1
Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) Consortium. (2018). Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clinical Trials, 1740774518795637.